Compare Franco-Nevada Corporation (FNV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Franco-Nevada Corporation is far larger — about 6.2× Spyre Therapeutics Inc. Common Stock's market cap, and Franco-Nevada Corporation pays a 0.72% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FNV | SYRE | |
|---|---|---|
Market Cap | $46.80B | $7.52B |
Volume | 310,692 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $108.92 |
52-Week Low | $183.97 | $22.18 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $45.79B | $6.52B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
